Business Today
Subscribe
PMS TodayUS NewsIndiaUPSTARTWeatherBT ShortsNRIEducationElection
BT GolfBT MindrushBT Best Banks
Search

COMPANIES

No Data Found

NEWS

No Data Found
Advertisement
News
markets
stocks
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd

Glenmark Life Sciences Ltd (GLS) Share Price

  • Sector: Pharmaceuticals (Small Cap)
  • Volume: 58,953
Apr 25, 2025 Closed
  • NSE
  • BSE
Share
  • Whatsapp
  • Twitter
  • Facebook
₹1,015.40
₹-18.20 (-1.76%)
996.50Low
Today’s Performance
1,034.10High
743.85Low
52 Week’s Performance
1,335.10High

bt_logoStock Analysis

bt_logoStock Performance

  • 1 Day-3.00%
  • 1 Week4.50%
  • 1 Month-2.87%
  • 3 Months-10.06%
  • 6 Months-0.71%
  • 1 Year25.06%
  • 3 Years28.23%
  • 5 Years-%

bt_logoPeer Comparison

Sun Pharmaceutical Industries Ltd
Divis Laboratories Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Price

₹1,784.40

Sun Pharmaceutical Industries Ltd

₹6,057.50

Divis Laboratories Ltd

₹1,537.90

Cipla Ltd

₹3,251.10

Torrent Pharmaceuticals Ltd

bt_logoStock Summary

  • Face Value (₹)2.00
  • Beta0.52
  • 52-Week Low (₹)743.85
  • 52-Week High (₹)1,335.10
  • Price-to-Book (X)*4.97
  • Dividend Yield (%)2.18
  • Price-to-Earnings (P/E) (X)*28.58
  • Earnings Per Share (₹)36.05
  • Market Cap (₹ Cr.)*12,665.43
* Values as of last close price

bt_logoCOMPETITORS

BT TV

U.S. Treasury: IMF & World Bank Have Drifted From Core Mission, Are Wasting Resources7:14US Treasury Slams China’s Trade Model | Urges Urgent Global Rebalancing
The Power Of Presence - An Underrated Leadership Trait1:03The Power Of Presence - An Underrated Leadership Trait
Gold or Silver?| Jim Rogers: I’ll Buy More Gold If Prices Dip – Here’s Why0:43Gold or Silver? | Jim Rogers: I’ll Buy More Gold If Prices Dip – Here’s Why
After Pahalgam Bloodshed, India Strikes Back: Indus Treaty Halted, Borders Shut, Justice Promised3:59After Pahalgam Bloodshed, India Strikes Back: Indus Treaty Halted, Borders Shut, Justice Promised
PM Modi From Bihar Stage: “India Will Punish Pahalgam Attackers Beyond Their Imagination4:32PM Modi From Bihar Stage: “India Will Punish Pahalgam Attackers Beyond Their Imagination"
Market Masters | Kenneth Andrade On Trump Tariff Impact, Market Outlook, Sectors, Mutual Funds & More24:48Market Masters | Kenneth Andrade On Trump Tariff Impact, Market Outlook, Sectors, Mutual Funds & More
Gold at Historic Highs: Jim Rogers Explains Why He’s Holding and Still Buying Bullion0:43Gold At Historic Highs: Jim Rogers Explains Why He’s Holding And Still Buying Bullion
On Ground In Pahalgam: Terror Attack Empties The Valley’s Most Loved Tourist Town In Just Hours2:47On Ground In Pahalgam: Terror Attack Empties The Valley’s Most Loved Tourist Town In Just Hours
Akshay Bhagwat On Nestle’s Momentum V/S HUL’s Stagnation1:01Akshay Bhagwat On Nestle’s Momentum V/S HUL’s Stagnation
India Suspends Indus Water Treaty: Dry Days Ahead For Pakistan & Its Economy?4:10India Suspends Indus Water Treaty: Dry Days Ahead For Pakistan & Its Economy?
View more

bt_logoFinancial Analysis

Income Statement (₹ Cr.)

No data for consolidated quarterly Income Statement.

Balance Sheet (₹ Cr.)

No data for consolidated quarterly Income Statement.

Cash Flow (₹ Cr.)

No data for consolidated quarterly Income Statement.

bt_logoRatio Analysis

Return on Equity (%)
No Data For consolidated ROE.
Return on Assets (%)
No Data For consolidated ROE.
Price-to-Earnings (P/E) (X)
No Data For consolidated ROE.
Price to Book (x)
No Data For consolidated ROE.
Return on Capital Employed (%)
No Data For consolidated ROE.
Enterprise Value to EBITDA (X)
No Data For consolidated ROE.
Net Profit Margin (%)
No Data For consolidated ROE.
Gross Profit Margin (%)
No Data For consolidated ROE.
EBITDA Margin (%)
No Data For consolidated ROE.

bt_logoShare Holding Pattern

Summary (As on 31 Mar 2025)
Promoters (75.00%)
Domestic institutional investors (5.19%)
Foreign Institutional Investors (7.23%)
Public & Others (10.80%)
Government Holding (0.00%)
Corporate Holding (1.79%)

bt_logoDeals

25 Jan, 2024SELL
BNP PARIBAS ARBITRAGE
Qty151173
Average Price₹799.55
25 Jan, 2024BUY
SOCIETE GENERALE
Qty151173
Average Price₹799.55
*Single trade that involves transaction of a minimum quantity of 5 lakh shares or a minimum value of ₹ 10 crore.

bt_logoFAQ's

What was Glenmark Life Sciences Ltd share price previously?
Glenmark Life Sciences Ltd share price was down by -1.76% from the previous closing price of ₹1,033.60.
Who are peers of Glenmark Life Sciences Ltd?
The peers of Glenmark Life Sciences Ltd are Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Lupin Ltd.
Who is/are the promoter/promoters of Glenmark Life Sciences Ltd?
The promotor/promotors of Glenmark Life Sciences Ltd are Yasir Yusufali Rawjee, Vinod Naik, Manju Agarwal, Taruvai Laxminarayanan Easwar, HIREN KARSANBHAI PATEL, KAUSHIKBHAI NANDUBHAI PATEL, Savan Godialwala, Rudalf Corriea.
What has been 52-week high of Glenmark Life Sciences Ltd stocks?
The highest price of Glenmark Life Sciences Ltd stock is ₹1,335.10 in the last 52-week.
What is the share price of Glenmark Life Sciences Ltd (ALIVUS) today on NSE?
As on Apr 25, 2025 Glenmark Life Sciences Ltd (ALIVUS)’s share price on NSE is Rs 1015.4
What is the market cap of Glenmark Life Sciences Ltd (ALIVUS)?
The current market capitalisation of Glenmark Life Sciences Ltd (ALIVUS) is 12,665.43 crores
What is Glenmark Life Sciences Ltd Share symbol?
The symbol of Glenmark Life Sciences Ltd is ALIVUS.
What is the PE ratio of Glenmark Life Sciences Ltd (ALIVUS)?
The current PE ratio of Glenmark Life Sciences Ltd (ALIVUS) is 28.58.
What is the PB ratio of Glenmark Life Sciences Ltd (ALIVUS)?
The current PB ratio of Glenmark Life Sciences Ltd (ALIVUS) is 4.97.
Today’s High & Low share prices of Glenmark Life Sciences Ltd (ALIVUS) on NSE?
Today, the share price of Glenmark Life Sciences Ltd (ALIVUS) on NSE touched a high of Rs 1034.1 and a low of Rs 996.5
What price did Glenmark Life Sciences Ltd (ALIVUS) shares open on the NSE today?
On NSE, the share price of Glenmark Life Sciences Ltd (ALIVUS) opened at Rs 1033.6
What is the 52-week high of Glenmark Life Sciences Ltd (ALIVUS)?
The 52-week high price of Glenmark Life Sciences Ltd (ALIVUS) is Rs 1,335.10
What is the 52-week low of Glenmark Life Sciences Ltd (ALIVUS)?
The 52-week low price of Glenmark Life Sciences Ltd (ALIVUS) is Rs 743.85

bt_logoAbout Glenmark Life

Alivus Life Sciences Ltd, incorporated in the year 2011, has its registered office in Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213, 91-2189-234456/234246. The main industry in which Alivus Life Sciences Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln.

Auditor/Auditors for Alivus Life Sciences Ltd is/are Walker Chandiok & Co LLP. In the main management, HIREN KARSANBHAI PATEL is chairman and Rudalf Corriea is the company secretary for Alivus Life Sciences Ltd.

  • YYR
    Yasir Yusufali RawjeeManaging Director & CEO
  • VN
    Vinod NaikExecutive Director
  • MA
    Manju AgarwalIndependent Non Exe. Director
  • TLE
    Taruvai Laxminarayanan EaswarIndependent Non Exe. Director
  • HKP
    HIREN KARSANBHAI PATELChairman (Non-Executive)
  • KNP
    KAUSHIKBHAI NANDUBHAI PATELIndependent Director
  • SG
    Savan GodialwalaIndependent Director
  • RC
    Rudalf CorrieaCompany Sec. & Compli. Officer

bt_logoTop Stories

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.